We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Debiopharm to Acquire Products or Companies
News

Debiopharm to Acquire Products or Companies

Debiopharm to Acquire Products or Companies
News

Debiopharm to Acquire Products or Companies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Debiopharm to Acquire Products or Companies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Debiopharm Group™ (Debiopharm) has announced its decision to expand and optimize activities at Debiopharm Research & Manufacturing S.A., its industrial development and production facility in Martigny (Valais, Switzerland), through acquisition of industrial high value added activities or companies in the pharmaceutical, biotech or medtech field.

Debiopharm Research & Manufacturing S.A. boasts 35 years of expertise in drug development including chemical synthesis, formulation improvement and manufacturing. Major investments have been made since 2007 to automate the facility and increase its industrial capacity.

The objective is to expand industrial operations in Martigny by acquiring opportunities for optimization and production, generating a double-digit million revenue annually.

Expertise in R&D and manufacturing of hard-to-make pharmaceutical products, modern infrastructure combined with high tech GMP-compliant production, a logistic platform for worldwide delivery, established quality assurance and regulatory certification, as well as a central location in Europe are some of the features that will enable this objective to be met.

"We want to be the bridge between development and industrialization" says Cédric Sager, Chief Executive Officer of Debiopharm Research & Manufacturing S.A. "and supply Swiss-made products manufactured using state-of-the-art technology. Hard-to-make drugs, highly complex formulated drugs, biologic niche products, premium diagnostics and medical devices are on our wish-list".

Thierry Mauvernay, Delegate of the Board of Debiopharm Group, explains that "we have invested heavily during the last years to automate our site in Martigny as much as possible. Thanks to our efforts, we have increased our productivity. Our wish now is to acquire new industrial opportunities to strengthen our activity in Valais and support our development".

Advertisement